359 related articles for article (PubMed ID: 10817493)
1. Cancer vaccines.
Dalgleish AG
Br J Cancer; 2000 May; 82(10):1619-24. PubMed ID: 10817493
[No Abstract] [Full Text] [Related]
2. Cancer vaccines: training the immune system to fight cancer.
Meadows M
FDA Consum; 2004; 38(5):20-5. PubMed ID: 15595145
[No Abstract] [Full Text] [Related]
3. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
4. Tumor vaccines in 2010: need for integration.
Koos D; Josephs SF; Alexandrescu DT; Chan RC; Ramos F; Bogin V; Gammill V; Dasanu CA; De Necochea-Campion R; Riordan NH; Carrier E
Cell Immunol; 2010; 263(2):138-47. PubMed ID: 20434139
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines and immunotherapies: emerging perspectives.
Henderson RA; Mossman S; Nairn N; Cheever MA
Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
[TBL] [Abstract][Full Text] [Related]
6. Roadmap to a better therapeutic tumor vaccine.
Emens LA
Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
[TBL] [Abstract][Full Text] [Related]
7. Overview of tumor cell-based vaccines.
Copier J; Dalgleish A
Int Rev Immunol; 2006; 25(5-6):297-319. PubMed ID: 17169778
[TBL] [Abstract][Full Text] [Related]
8. Cellular vaccine therapy for cancer.
Armstrong AC; Eaton D; Ewing JC
Expert Rev Vaccines; 2002 Oct; 1(3):303-16. PubMed ID: 12901571
[TBL] [Abstract][Full Text] [Related]
9. Tumor antigens as surrogate markers and targets for therapy and vaccines.
Dalgleish A; Pandha H
Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunoediting and "spontaneous" tumor regression.
Sengupta N; MacFie TS; MacDonald TT; Pennington D; Silver AR
Pathol Res Pract; 2010 Jan; 206(1):1-8. PubMed ID: 19945228
[TBL] [Abstract][Full Text] [Related]
11. Immunologic aspects of cancer.
Sophocles AM; Nadler SH
Surg Gynecol Obstet; 1971 Aug; 133(2):321-31. PubMed ID: 4935594
[No Abstract] [Full Text] [Related]
12. Cancer vaccine development: on the way to break immune tolerance to malignant cells.
Mocellin S; Rossi CR; Nitti D
Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526
[TBL] [Abstract][Full Text] [Related]
13. Tissue vaccines for cancer.
Suckow MA; Heinrich J; Rosen ED
Expert Rev Vaccines; 2007 Dec; 6(6):925-37. PubMed ID: 18377356
[TBL] [Abstract][Full Text] [Related]
14. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
15. Interpreting cancer vaccine clinical trials.
Dranoff G
J Gene Med; 1999; 1(2):80-3. PubMed ID: 10738571
[TBL] [Abstract][Full Text] [Related]
16. The case for polyvalent cancer vaccines that induce antibodies.
Ragupathi G; Livingston P
Expert Rev Vaccines; 2002 Aug; 1(2):193-206. PubMed ID: 12901558
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell vaccines for cancer therapy.
Sprinzl GM; Kacani L; Schrott-Fischer A; Romani N; Thumfart WF
Cancer Treat Rev; 2001 Aug; 27(4):247-55. PubMed ID: 11545544
[TBL] [Abstract][Full Text] [Related]
18. DC-based cancer vaccines.
Gilboa E
J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349
[TBL] [Abstract][Full Text] [Related]
19. [Update on tumor immunology].
Fridman WH; Berger A; Lee RS; Tartour E
Bull Cancer; 1998 Jan; 85(1):29-30. PubMed ID: 9752341
[No Abstract] [Full Text] [Related]
20. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
